Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575525 | 0.92 | FASN (0.35) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575632 | 0.89 | FASN (0.35) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575584 | 0.88 | SLC6A2 (0.35) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20574806 | 0.86 | CCNC (0.38) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575557 | 0.86 | CCNC (0.39) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575566 | 0.86 | SLC6A2 (0.38) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575608 | 0.85 | FASN (0.37) | CCNCCDK8ROCK2ROCK1CCR2 | |
| SCHEMBL20576413 | 0.85 | FASN (0.37) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20576473 | 0.85 | FASN (0.37) | DRD4SIGMAR1CCNCCDK8ROCK2 | |
| SCHEMBL20575081 | 0.83 | SLC6A2 (0.39) | DRD4SIGMAR1CCNCCDK8ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | DRD4 4825/4885SIGMAR1 2803/4885CCNC 2802/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | DRD4 4825/4885SIGMAR1 2803/4885CCNC 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.